{
    "nct_id": "NCT05519579",
    "official_title": "Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia",
    "inclusion_criteria": "* Adults receiving first cycle of blinatumomab for relapse/refractory or MRD-positive B-cell Acute Lymphoblastic Leukemia\n* Adequate renal and hepatic function\n* Negative for HIV\n* Negative serum pregnancy test, if applicable\n* ECOG 0-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active CNS involvement by ALL\n* Relative CNS disorders (seizure, paresis, aphasia, Cerebrovascular ischemia/hemorrhage, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, coordination or movement disorder)\n* Contraindication to receive intrathecal methotrexate\n* Prior treatment with blinatumomab\n* Active malignancy other than ALL\n* Active infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator",
    "miscellaneous_criteria": ""
}